Human clinical data from TCGA and OncoLnc databases suggest that the RCC patients with higher expression of TR4, lncTASR, or AXL all have significantly shorter overall survival (Fig. 5a–c), and a positive correlation between expression of TR4 and AXL was also found from TCGA database [24] (n = 522) (Fig. 5d). The gene discussed is AXL; the disease is renal cell carcinoma.